Jasper Therapeutics (NASDAQ:JSPR) Upgraded by Wall Street Zen to Hold Rating

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

JSPR has been the topic of a number of other reports. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Jasper Therapeutics has an average rating of “Hold” and a consensus target price of $12.00.

Jasper Therapeutics Stock Down 5.6%

JSPR opened at $0.69 on Friday. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $3.25. The business has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $1.00. The company has a market cap of $19.28 million, a PE ratio of -0.21 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. As a group, sell-side analysts expect that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Knott David M Jr boosted its position in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock worth $332,000 after purchasing an additional 10,000 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at about $46,000. Engineers Gate Manager LP purchased a new position in shares of Jasper Therapeutics in the 2nd quarter valued at about $78,000. Renaissance Technologies LLC lifted its stake in shares of Jasper Therapeutics by 9.0% in the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after purchasing an additional 18,683 shares during the period. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at about $35,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.